

Bloomberg	ABCAP IN
Equity Shares (m)	2607
M.Cap.(INRb)/(USDb)	534.2 / 6.3
52-Week Range (INR)	247 / 149
1, 6, 12 Rel. Per (%)	3/5/-19
12M Avg Val (INR M)	1137

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
PBT Break-up			
NBFC	33.6	41.2	52.4
Housing	4.2	6.5	8.4
AMC	12.5	13.6	15.4
Life Insurance	1.6	1.8	2.0
Health Insurance	0.1	0.8	1.5
Other businesses	1.4	2.0	1.7
Consolidation adjustments	1.5	1.6	1.7
Consol PBT	54.8	67.4	83.2
Consol PAT Post MI and others	33.3	38.7	48.1
Growth (%)	-0.1	16.0	24.3
RoE (%)	11.6	12.1	13.6
Con PE	15.9	13.6	11.0
Cons. PBV	1.7	1.6	1.4

Shareholding pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	68.8	68.9	69.0
DII	9.8	9.5	7.5
FII	8.8	9.2	11.8
Others	12.6	12.4	11.7

FII Includes depository receipts

CMP: INR205

TP: INR250 (+22%)

Buy

Strong growth in HFC AUM; NBFC NIM to improve hereon

Consol. PAT grew 6% YoY; unsecured MSME segment seeing stress

- Aditya Birla Capital (ABCAP)'s 4QFY25 consolidated revenue grew 13% YoY to ~INR141b and consolidated PAT grew ~6% YoY to ~INR8.65b. FY25 consol. PAT grew ~8% YoY to INR31.4b.
- The amalgamation of Aditya Birla Finance (ABFL) with Aditya Birla Capital has been successfully completed after obtaining all requisite approvals. The appointed date of the amalgamation is 1st Apr'24, and the effective date is 1st Apr'25. Post-amalgamation, ABCAP operates under two business segments: the NBFC lending business and the investment business, through which it holds investments in its subsidiaries, JVs, and associates.
- Management shared that the amalgamation has resulted in the release of ~INR30-35b of capital, which is expected to support the company's growth ambitions for the next 12-18 months.

NBFC: AUM up ~20% YoY; NIM contracts ~10bp QoQ

- NBFC Loan book grew ~20% YoY and 6% QoQ to ~INR1.26t. 4QFY25 disbursements grew ~8% YoY and 28% QoQ to ~INR195b. Loans to Retail, SME and HNI customers constitute 64% of the total loan portfolio.
- Management remains confident of delivering robust loan growth, targeting a ~25% CAGR in the overall portfolio over the next three years, with a target to double the loan book within this period. The company expects all business segments to register growth in FY26, with a continued increase in the contribution from the retail and MSME segments.
- Asset quality improved QoQ, with GS2 + GS3 assets declining ~50bp QoQ to ~3.8%.
- NIM contracted ~10bp QoQ as yields compressed due to a reduction in personal and consumer (P&C) loans to 12% (PY: ~17%). Management highlighted that the P&C segment has now stabilized and is expected to grow going forward, which should lead to an expansion in yields and NIMs in the subsequent quarters.

HFC: Robust growth in HFC AUM; GS2+GS3 declines ~35bp QoQ

- HFC disbursement jumped ~98% YoY to ~INR58.2b and loan book grew 69% YoY to ~INR311b.
- Management expects the current business momentum to sustain and has guided for a significant improvement in RoA to ~2.0-2.2% over the next 8-10 quarters. This improvement is expected to be driven by better operating leverage, partially offset by a decline in NIMs, while credit costs are expected to remain broadly stable.
- NIM was largely stable QoQ at ~4.05%. RoA/RoE stood at 1.45%/11%
- Asset quality improved with GS3 declining ~33bp QoQ to ~0.66%. PCR rose ~15pp QoQ to ~55%.

Asset Management: QAAUM rose ~15% YoY

- The mutual fund quarterly average AUM (QAAUM) rose 15% YoY to INR3.82t. Individual monthly average AUM grew by 6% YoY to INR1.84t as of Mar'25.
- The domestic equity mix stood at ~44.3% (PQ: ~46.8%). Monthly SIP inflows grew ~5% YoY to ~INR13.2b in Mar'25.

Life Insurance: Individual FYP grew ~34% YoY; 13th month persistency rose to 88%

- Individual FYP grew 34% YoY to ~INR41b in FY25, while renewal premium grew 14% YoY.
- Net VNB margin stood at ~18% in FY25. 13M persistency rose to ~88% in Mar'25. Management has guided for a ~20-22% CAGR in individual FYP over the next three years, with a continued focus on expanding the VNB margin beyond 18%.

Health Insurance: Market share among SAHIs improves

- GWP in the health insurance segment grew 33% YoY to ~INR49.4b. The combined ratio improved to 105% (from ~110% YoY).
- ABHI's market share among standalone health insurers (SAHIs) rose from 11.2% in the previous year to 12.6% in Mar'25.

Highlights from the management commentary

- The company is exploring collaborations with select marquee digital platforms, where sourcing will be driven by partners, while ABCL will manage underwriting and collections.
- Udyog Plus, the company's comprehensive B2B ecosystem platform, has continued to scale rapidly, reaching an AUM of over INR35b in less than two years since its launch. Notably, the ABG ecosystem contributes ~50% of the disbursements on the Udyog plus.

Valuation and view

- ABCAP continued to exhibit an improvement in operational metrics in 4QFY25. Loan growth remained healthy across both the HFC and NBFC segments, accompanied by a further improvement in asset quality. While NIMs in the NBFC business witnessed some contraction during the quarter, management has guided for NIM improvement in the subsequent quarters, supported by a favorable shift in its product mix.
- We expect a consolidated PAT CAGR of ~24% over FY25-27E. The thrust on cross-selling, investments in digital, and leveraging 'One ABC' will lead to healthy return ratios, even as we build in a consolidated RoE of ~14% by FY27.

Reiterate BUY with an SoTP (Mar'27E)-based TP of INR250.

ABCL: SOTP – Mar'27

	Stake	Value (INR B)	Value (USD B)	INR per share	% To Total	Rationale
NBFC	100	332	3.9	128	51	❖ 1.3x PBV
HFC	100	54	0.6	21	8	❖ 1.1x PBV
AMC	45	104	1.2	40	16	❖ 20x Earnings
LI	51	118	1.4	45	18	❖ 1.2x EV
Health Ins	46	35	0.4	14	5	❖ 1.0x GWP
Others		5	0.1	2	1	
Target Value		649	7.6	250	100	

Quarterly Performance

(INR M)

Y/E March	FY24				FY25				FY24	FY25
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
ABFSL - NBFC arm										
Net Income	14,337	15,200	16,488	16,926	17,089	17,114	17,339	17,764	62,951	69,306
Opex	4,370	4,370	5,320	5,500	5,080	5,310	5,410	5,500	19,560	21,300
Cost to Income Ratio (%)	30.5	28.7	32.3	32.5	29.7	31.0	31.2	31.0	31.1	30.7
Operating Profits	9,967	10,830	11,168	11,426	12,009	11,804	11,929	12,264	43,391	48,006
Provisions	3,060	3,470	3,500	3,490	3,680	3,360	3,880	3,490	13,520	14,410
Profit Before Tax	6,907	7,360	7,668	7,936	8,329	8,444	8,049	8,774	29,871	33,596
Change YoY (%)	50.6	50.9	42.1	31.4	20.6	14.7	5.0	10.6	42.9	12.5
Consolidated Earnings										
Cons PBT Before JV Interest	10,105	10,615	10,785	13,733	12,437	16,057	11,840	14,413	46,140	54,746
Growth YoY %	43.7	25.6	-70.1	45.7	23.1	51.3	9.8	5.0	-24.4	18.7
Lending	7,752	8,330	8,669	8,885	9,177	9,482	9,147	9,985	33,635	37,791
NBFC	6,907	7,360	7,668	7,936	8,329	8,444	8,049	8,774	29,871	33,600
HFC	845	969	1,002	949	848	1,038	1,098	1,211	3,765	4,194
AMC	2,403	2,368	2,635	2,676	3,045	3,351	2,999	3,050	10,084	12,450
Life Insurance	200	424	521	831	215	443	432	495	1,980	1,580
Health Insurance	-625	-795	-1,313	913	-540	-653	-835	2,089	-1,820	60
Others*	375	288	272	428	540	3,434	97	-1,206	2,261	2,865
Taxes	2,460	2,840	2,890	2,710	2,930	3,560	3,040	4,750	13,180	14,280
Tax rate %	24.3	26.8	26.8	19.7	23.6	22.2	25.7	33.0	28.6	26.1
Profit After Tax	6,660	7,250	7,600	8,550	7,650	8,540	7,150	8,860	32,960	32,200
MI and Others	170	200	250	430	200	200	160	210	-3,940	770
PAT post MI and other adjustments	6,490	7,050	7,350	8,120	7,450	8,340	6,990	8,650	29,020	31,430
Growth YoY %	51	44	39	33	15	18	-5	7	56	8
Gain on Sale of stake in Subs/associate (net of tax)		0			140	1,660	90	0	4,330	1,890
Reported PAT	6,490	7,050	7,350	8,120	7,590	10,000	7,080	8,650	33,350	33,320
Growth YoY %		44.5			16.9	41.8	-3.7	6.5	55.8	-0.1

Details on lending business

Loans (INR B)	1004	1090	1151	1241	1277	1379	1462	1574		
Change YoY (%)	43.7	40.7	33.9	31.5	27.2	26.6	26.9	26.9		
NBFC	859	935	986	1056	1073	1147	1194	1264		
Change YoY (%)	48.5	43.9	35.1	31.1	24.9	22.7	21.1	19.6		
HFC	145	154	165	184	204	232	267	311		
Change YoY (%)	20.4	24.0	27.3	33.4	40.6	50.5	61.5	68.6		
Net Interest Margins										
NBFC	6.98	6.87	6.88	6.86	6.56	6.29	5.99	6.86		
HFC	5.11	4.88	4.63	4.39	4.24	4.22	4.06	4.39		
GNPA %										
NBFC	2.80	2.64	2.59	2.50	2.51	2.50	2.27	2.30		
HFC	2.67	2.63	2.18	1.82	1.60	1.30	0.99	0.66		

Details on Other business

AMC Business										
QAAUM (INR B)	3,084	3,235	3,247	3,458	3,676	4,004	4,009	4,056		
Change YoY (%)	5.4	10.1	10.8	20.8	19.2	23.8	23.5	17.3		
Life Ins - 13th Mt persistency	88.0	87.0	87.0	88.0	88.0	88.0	87.0	88.0		

* Others includes Health Ins, PE, AB Money and inter group adjustment; Numbers may vary from actual reporting due to difference in reporting



Highlights from the management commentary

NBFC

- Given the early warning signals and macro stress, it has calibrated its sourcing from few fintech partners.
- Credit costs declined 22bp YoY and 15bp QoQ.
- GS2 + GS3 declined 71bp YoY and 47bp QoQ to 3.78%.
- GS3 PCR stood at 45%, stable QoQ.
- Operating environment has stabilized.
- ABCD App continues to scale up well and contributes 5% of the PL disbursements.
- Looking at collaborating with few marquee digital platforms wherein the sourcing will be done by partners and the underwriting/collections will be done by ABCL.
- NBFC 4QFY25 PAT grew ~11% YoY and ~9% QoQ to INR6.52b. RoA in 4QFY25 increased by 15bp QoQ to 2.25%. FY25 RoA stood at 2.27%.
- Confident of growing the overall portfolio at a CAGR of 25% over the next three years. It will be looking at doubling the loan-book over the next three years.
- NBFC Portfolio grew 20% YoY and 6% QoQ to INR1.26t.
- NIM (incl. Fee income) expanded 6bp QoQ.
- Over the last three years, it has doubled its AUM and profit pool. It has built a granular retail and MSME portfolio.
- AUM for business loans to MSME grew 20% YoY.
- P&C Loans segment will start registering calibrated growth in the coming years.
- MSME segment contributes significant to the secured business.
- CIR of 30.8% | FY25 Opex to AUM improved to 1.94% (PY: 2.26%)
- GS3 Loans at 2.24% declined 27bp YoY and credit costs declined 15bp QoQ to 1.21%.
- Credit costs stood at 1.3%, well within its state guidance of 1.5%.
- FY25 PAT grew 13% YoY.
- Expects all business segments to grow in FY26 and share of Retail/MSME segment to improve.
- Share of direct sourcing will improve and operating leverage will play out.
- NIM compression is on account of the change in the product mix. P&C declined to 12-13% in the Loan mix from ~20% at its peak. P&C has now stabilized and will grow from here - which will result in an expansion in yields and NIM.
- Unsecured segments comprises of Supply Chain Financing (20%) and small-ticket unsecured Term Loans (80%). Almost 50% of that the unsecured portfolio is guaranteed by credit guarantee. It does not get written-off at 180dpd since it is backed by a guarantee from SIDBI. For leveraged customers, it has tightened the underwriting.
- 5-6% of the annual disbursements were from portfolio buyouts.
- Unsecured business flow rate is 0.8% (and they have been largely stable) and it should see some improvement there.
- Credit costs declined to 1.31% (FY24: 1.5%). Strengthened its underwriting and leverage of the customer inputs have gone into the scorecards. Tracking all the cohorts closely and strengthened its collection infrastructure.

- P&C yields stood at 18-19% and a ~200bp improvement in the product mix should help it expand its NIM.
- Most of its bank borrowings are 3M and 1M MCLR. Repo-linked bank borrowings will be only ~10%.
- Entire range of products, including Personal & Consumer, might look at one or two more products. Will look to sweat its existing branches and branches which it will open in the next 6-9 months.
- On the Liabilities side, ~65% are floating and on the assets side, ~71% is floating. As it grows personal and consumer segments - STPL - which are fixed in nature, product mix should help it improve its yields and NIM
- Loan Mix: 75% of it will be Retail and SME and P&C can go up to ~20%. Growth in unsecured businesses and NIM expansion will boost its RoA.

HFC

- Created a full-stack franchise focused on both prime and affordable segments.
- Crossed the monthly disbursement rate of ~INR22b in Mar'25.
- GS3 declined ~33bp QoQ to 0.66%.
- RoA stood at 1.26% and RoE of 11.03% in FY25.
- HFC AUM grew 69% YoY to INR311b.
- Infused ~INR3b in the HFC subsidiary in 4Q and the total infusion in HFC stood at ~INR12b in FY25.
- Disbursements for FY25 stood at INR176.5b, up 109% YoY.
- Portfolio Quality: GS3 stood at 0.66%, down 115bp YoY. 95% of its collections are collected by its Fin connect platform.
- Delivered consistent growth across segments. Focus remains on strengthening all its core areas.
- Developer Finance: 280-300 developers in the Developer Finance portfolio and average exposures of INR250-300m. Cost of construction will be INR2.5-3b. Developer book yields of 13.0-13.25% and retail book has blended yields of 10.25%.
- CRAR stood at 16.54% (compared to the regulatory requirement of ~15%).
- Expects the current growth momentum to continue and expects RoA to improve significantly. Guided for RoA to improve significantly to 2.0-2.2% over the next 8-10 quarters. Improvement in RoA will come from the improvement in operating leverage and opex to assets will decline by 120-130bp. NIM might decline by 25-30bp; Credit costs will remain in the same range.

Life Insurance

- VNB Margin of 18% in FY25.
- Expanded its market share by 66bp in FY25.
- Partnership business grew 34% YoY; Managed respectable mind share in its IDFC First and Axis Bank partnerships.
- 11 Bank partnerships; Entered into a partnership with Equitas SFB and will start business in FY26.
- Digital collections account for 81% of the individual premium collections.
- 14th Month persistency: 81%
- AUM stood at INR995b, up 15% YoY. Crossed AUM of INR1t in Apr'25.
- Will continue to focus on its proprietary channel.

- Guided for CAGR of 22-25% in Business growth and VNB Margin of >18%.
- Positive operating variance is better experience in lapses and contribution of group business profit. Assumption variance - persistency, lapse in some of its products particularly non-par. Mortality experience has been better. Assumption variance change would have contributed ~100bp to the VNB Margins.

Omnichannel Architecture for distribution

- ABCD went live about a year ago.
- Udyog Plus - Comprehensive B2B ecosystem continued to scale up and reached AUM of >INR35b in less than two years of its launch. ABG Ecosystem contributes ~50% of the disbursements on Udyog Plus.

Standalone Financials

- Standalone PAT grew 6% YoY to INR6.54b.
- Tier 1 stood at 15.93% and Total CRAR stood at 18.22%.
- Standalone RoE stood at 14.22% in 4QFY25.

Health Insurance

- PAT of INR60m in FY25.
- Growth momentum continues, with 34% YoY growth in 4QFY25 – fastest-growing SAHI.
- Market share in SAHI stood at 12.6% (up 38bp YoY).
- Added Bank of India as a partner.

Merger


- On the back of the merger, ~INR30-35b worth of capital got released and it will take care of 12-18 months of growth requirement.

ABCD App

- Predominantly working on origination of PL, Housing Business and AMC business.
- Monthly disbursement run-rate of ~INR1b in Personal and Consumer loans.


Key exhibits

Exhibit 1: NBFC loan book grew ~20% YoY




Source: MOFSL, Company

Exhibit 2: HFC loan book grew 69% YoY




Source: MOFSL, Company

Exhibit 3: NBFC – Loan mix as of Mar'25 (%)




Source: MOFSL, Company; Others include Promoter and others

Exhibit 4: NBFC GS3 was stable at ~2.3%




Source: MOFSL, Company; Note: NBFC segment

Exhibit 5: AMC segment - Total AAUM stood at ~INR4.1t




Source: MOFSL, Company

Exhibit 6: AMC: PBT margin stable QoQ



Source: MOFSL, Company, *% of AAUM Annualized


Exhibit 7: Product mix in ABSLI (%)



Source: MOFSL, Company


Note: Split of PAR and Non-PAR not disclosed over eleven quarters

Exhibit 8: The 13-month persistency rose to ~88%



Source: MOFSL, Company

Exhibit 9: Trend in Health Insurance GWP (INR m)



Source: MOFSL, Company

Financials and valuations

	(INR m)								
Y/E MARCH	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
NBFC	13,280	10,529	10,314	14,883	20,902	29,871	33,600	41,247	52,410
Housing	1,073	1,362	1,764	2,533	3,085	3,765	4,194	6,475	8,425
AMC	6,468	6,609	6,958	8,948	7,939	10,084	12,450	13,576	15,442
Life Insurance	1,315	1,370	1,510	1,750	1,960	1,980	1,580	1,817	2,035
Health Insurance		-2,460	-2,000	-3,087	-2,180	-1,820	60	800	1,500
Other Businesses	414	590	931	1,217	1,439	1,364	1,386	1,953	1,724
Consolidation Adjustments	-2,011	-1,128	256	-8,396	-6,909	897	1,479	1,579	1,679
Consolidated PBT	20,538	16,872	19,733	17,848	26,237	46,140	54,750	67,447	83,214
Taxes	7,681	5,804	6,096	6,267	8,112	13,180	17,450	20,909	25,796
<i>Tax Rate (%)</i>	<i>37.4</i>	<i>34.4</i>	<i>30.9</i>	<i>35.1</i>	<i>30.9</i>	<i>28.6</i>	<i>31.9</i>	<i>31.0</i>	<i>31.0</i>
Consolidated PAT	12,857	11,068	13,637	11,582	18,125	32,960	37,300	46,539	57,418
Share of JV and MI Adjustments	1,620	1,899	2,368	3,868	2,443	3,940	5,890	7,885	9,353
Other Adjustments	20	14	-2	1,610	27,390	4,330	1,910		
Consolidated PAT Post MI	11,237	9,169	11,269	17,060	47,958	33,350	33,320	38,653	48,065
% of Total PBT	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
NBFC	64.7	62.4	52.3	83.4	79.7	64.7	61.4	61.2	63.0
Housing	5.2	8.1	8.9	14.2	11.8	8.2	7.7	9.6	10.1
AMC	31.5	39.2	35.3	50.1	30.3	21.9	22.7	20.1	18.6
Life Insurance	6.4	8.1	7.7	9.8	7.5	4.3	2.9	2.7	2.4
Health Insurance	0.0	-14.6	-10.1	-17.3	-8.3	-3.9	0.1	1.2	1.8
Other Businesses	2.0	3.5	4.7	6.8	5.5	3.0	2.5	2.9	2.1
Consolidation Adjustments	-9.8	-6.7	1.3	-47.0	-26.3	1.9	2.7	2.3	2.0
Consolidated PBT	100.0								
Change YoY %	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
NBFC	16.6	-20.7	-2.0	44.3	40.4	42.9	12.5	22.8	27.1
Housing	352.3	26.9	29.5	43.6	21.8	22.0	11.4	54.4	30.1
AMC	23.6	2.2	5.3	28.6	-11.3	27.0	23.5	9.0	13.7
Life Insurance	0.8	4.2	10.2	15.9	12.0	1.0	-20.2	15.0	12.0
Other Businesses	-16.0	42.7	57.8	30.8	18.3	-5.3	1.7	40.9	-11.7
Consolidation Adjustments	-13.0	-43.9							
Consolidated PBT	25.6	-17.9	17.0	-9.6	47.0	75.9	18.7	23.2	23.4
Taxes	33.2	-24.4	5.0	2.8	29.4	62.5	32.4	19.8	23.4
Consolidated PAT	21.5	-13.9	23.2	-15.1	56.5	81.8	13.2	24.8	23.4
Minority Interest	-7.2	17.3	24.7	63.3	-36.8	61.3	49.5	33.9	18.6
Consolidated PAT Post MI	27.2	-18.4	22.9	51.4	181.1	-30.5	-0.1	16.0	24.3

Financials and valuations

BALANCE SHEET									(INR m)
Y/E MARCH	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
ESC	22,014	24,138	24,153	24,163	24,180	26,000	26,070	25,937	25,937
Reserves and Surplus	73,110	1,01,620	1,13,273	1,30,758	1,78,928	2,42,172	2,77,817	3,08,718	3,47,431
Networth	95,124	1,25,758	1,37,426	1,54,921	2,03,108	2,68,173	3,03,887	3,34,655	3,73,368
Non-Controlling Interest	11,574	13,196	14,848	15,986	15,093	18,205	19,583	27,469	36,821
Other Capital Instruments	0								
Borrowings	5,63,242	5,56,298	5,26,750	5,80,519	8,43,208	10,95,401	13,93,474	18,06,733	22,42,834
Change (%)	26.5	-1.2	-5.3	10.2	45.3	29.9	27.2	29.7	24.1
Insurance Business Related	4,01,500	4,12,645	5,24,765	6,08,734	6,90,899	8,53,885	9,83,506	10,81,856	11,90,042
Change (%)	10.1	2.8	27.2	16.0	13.5	23.6	15.2	10.0	10.0
Other liabilities	25,480	30,020	39,175	51,235	55,233	85,355	90,164	94,958	1,22,255
Change (%)	-18.7	17.8	30.5	30.8	7.8	54.5	5.6	5.3	28.7
Total Liabilities	10,96,920	11,37,917	12,42,963	14,11,395	18,07,541	23,21,018	27,90,614	33,45,671	39,65,319
Customer assets	6,37,935	6,32,618	6,17,017	6,92,424	9,87,538	13,16,047	16,04,726	20,41,754	25,20,159
Change (%)	22.6	-0.8	-2.5	12.2	42.6	33.3	21.9	27.2	23.4
Fixed Assets	9,262	12,550	13,038	13,500	13,228	17,466	20,513	18,603	20,422
Change (%)	6.4	35.5	3.9	3.5	-2.0	32.0	17.4	-9.3	9.8
Insurance Business Related	4,14,145	4,28,267	5,48,472	6,32,012	7,07,526	8,66,583	10,02,672	11,08,007	12,24,888
Change (%)	10.6	3.4	28.1	15.2	11.9	22.5	15.7	10.5	10.5
Other assets	35,578	64,483	64,437	73,459	99,250	1,20,923	1,62,703	1,77,307	1,99,850
Change (%)	4.8	81.2	-0.1	14.0	35.1	21.8	34.6	9.0	12.7
Total Assets	10,96,920	11,37,917	12,42,963	14,11,395	18,07,541	23,21,018	27,90,614	33,45,671	39,65,319

Y/E MARCH	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
NBFC	74,165	80,782	88,379	98,604	1,14,262	1,52,435	1,85,936	2,16,624	2,55,617
Housing	11,903	13,829	15,192	17,210	19,680	22,598	37,831	42,875	49,438
AMC	12,154	13,041	17,109	21,896	25,204	32,160	37,040	41,407	45,796
Life Insurance	24,488	26,574	26,574	29,368	32,086	38,041	42,432	44,249	46,284
Other Businesses	2,322	2,112	2,799	3,178	3,786	4,799	3,958	9,658	11,182
Consolidation Adjustments	-18,335	2,618	2,223	652	23,182	36,345	16,273	7,312	1,873
Consolidated Networth	1,06,698	1,38,954	1,52,274	1,70,907	2,18,201	2,86,378	3,23,471	3,62,124	4,10,189
Of which Non-controlling Int	11,574	13,196	14,848	15,986	15,093	18,205	19,583	27,469	36,821
Consolidated NW Post NCI	95,124	1,25,758	1,37,426	1,54,921	2,03,108	2,68,173	3,03,887	3,34,655	3,73,368

% of Total Network	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
NBFC	69.5	58.1	58.0	57.7	52.4	53.2	57.5	59.8	62.3
Housing	11.2	10.0	10.0	10.1	9.0	7.9	11.7	11.8	12.1
AMC	11.4	9.4	11.2	12.8	11.6	11.2	11.5	11.4	11.2
Life Insurance	23.0	19.1	17.5	17.2	14.7	13.3	13.1	12.2	11.3
Other Businesses	2.2	1.5	1.8	1.9	1.7	1.7	1.2	2.7	2.7
Consolidation Adjustments	-17.2	1.9	1.5	0.4	10.6	12.7	5.0	2.0	0.5
Consolidated Network	100.0								

Change YoY %	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
NBFC	17.5	8.9	9.4	11.6	15.9	33.4	22.0	16.5	18.0
Housing	58.7	16.2	9.9	13.3	14.4	14.8	67.4	13.3	15.3
AMC	4.7	7.3	31.2	28.0	15.1	27.6	15.2	11.8	10.6
Life Insurance	5.1	8.5	0.0	10.5	9.3	18.6	11.5	4.3	4.6
Other Businesses	-8.6	-9.1	32.5	13.5	19.1	26.7	-17.5	144.0	15.8
Consolidation Adjustments	51.3	-114.3	-15.1	-70.7	3,456.2	56.8	-55.2	-55.1	-74.4
Consolidated Net-worth	11.2	30.2	9.6	12.2	27.7	31.2	13.0	11.9	13.3

Y/E MARCH	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Valuations									
Consolidated BV	43	52	57	64	84	103	117	129	144
Change YoY	11	21	9	13	31	23	13	11	12
Con PBV	4.7	3.9	3.6	3.2	2.4	2.0	1.7	1.6	1.4
Consolidated EPS	5.1	3.8	4.7	7.1	8.5	11.2	12.8	14.9	18.5
Change YoY	27	-26	23	51	20	31	15	17	24
Con PE	39.8	53.4	43.5	28.8	23.9	18.2	15.9	13.6	11.0
Consolidated ROE	12.5	8.3	8.6	11.7	11.5	12.3	11.6	12.1	13.6

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH00000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.